Results 181 to 190 of about 611,894 (312)

Recombinant DNA Research: Proposed Actions Under the Guidelines

, 1997
National Institutes of Health [NIH] (United States). Office of Recombinant DNA Activities
core  

Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies

Advanced Science, EarlyView.
This study presents a 3D embedded bioprinting platform that recapitulates key stromal features of the tumor microenvironment using fibroblasts and lung‐derived ECM. The model enables functional assessment of CAR‐NK cells and provides a versatile tool to support the development of next‐generation immunotherapeutic strategies against solid tumors ...
Dahong Kim, Seona Jo, In‐Hwan Jang, Yu‐Jin Kim, Youngmee Jung, Junhyoung Ahn, Hyungjun Lim, Jae Jong Lee, Kangwon Lee, Tae‐Don Kim, Su A Park   +10 more
wiley   +1 more source

Assessment of Diagnostic Efficacy of Engineered ESAT-6 Linear Epitopes Based on IFN-γ Secretion in Tuberculosis. [PDF]

Iran J Biotechnol
Jokar A, Mohammadi-Sichani M, Jafarisani M, Beheshti-Maal K, Hosseinzadeh A.   +4 more
europepmc   +1 more source

Recombinant DNA is safe [PDF]

Nature, 1978
openaire   +2 more sources

Recombinant DNA Advisory Committee (minutes of meeting 6 October 1989)

, 1989
National Institutes of Health [NIH] (United States). Recombinant DNA Advisory Committee
core  

UCHL3 Regulates Subgenomic Flaviviral RNA Condensates to Promote Virus Propagation

Advanced Science, EarlyView.
ABSTRACT Flavivirus subgenomic RNAs (sfRNAs) antagonise antiviral defences, yet how sfRNAs are organized and maintained in cells remains poorly understood. Here we identify ubiquitin C‐terminal hydrolase L3 (UCHL3) as a post‐translational regulator of flavivirus sfRNA stability and function.
Oscar Trejo‐Cerro, Anna Beekmayer‐Dhillon, Qi Wen Teo, Lewis Siu, Ming Yuan Li, Kate J. Heesom, Adán Pinto‐Fernández, Sumana Sanyal   +7 more
wiley   +1 more source

ADMINISTRATIVE PRACTICES SUPPLEMENT TO THE NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT DNA MOLECULES: POLICIES AND ADMINISTRATIVE PROCEDURES FOR RECOMBINANT DNA RESEARCH SUBJECT TO THE NIH GUIDELINES

, 1979
National Institute of General Medical Sciences (United States). Office of Recombinant DNA Activities
core  

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Enhancement of RecET-mediated in vivo linear DNA assembly by a xonA mutation. [PDF]

PLoS One
Sawitzke JA, Costantino N, Caballero AC, Hutchinson E, Barenghi A, Thomason LC, Court DL.   +6 more
europepmc   +1 more source

Prenatal Gene Transfer: Scientific, Medical, and Ethical Issues: A Report of the Recombinant DNA Advisory Committee

, 2000
National Institutes of Health [NIH] (United States). Recombinant DNA Advisory Committee
core